Genome BC Initiative Will Spearhead Development of AML Test to Guide Treatment
July 06, 2011
Genome BC Initiative Will Spearhead Development of AML Test to Guide Treatment
The goal is to analyze a variety of genomic techniques, including sequencing, to develop a test that will determine whether AML patients should receive chemotherapy or stem cell transplantation.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BC Cancer Agency Developing Sequencing-Based AML Test to Stratify Patients for Different Treatments
September 14, 2011 / Clinical Sequencing News - Swedish Project Will Sequence Tumor Exomes to Study Drug Resistance, Develop Companion Tests
August 31, 2011 / Clinical Sequencing News - Quake Group Issued Patent for Detection of Fetal Aneuploidy with Next-Gen Sequencing
August 31, 2011 / Clinical Sequencing News - People in the News
August 31, 2011 / Clinical Sequencing News - Cost-Effectiveness Analysis Can Determine Which Colorectal Cancer Patients Should Not be Sequenced
August 24, 2011 / Clinical Sequencing News